Medpace (NASDAQ: MEDP) director exercises 6,472 options at $54.99

Rhea-AI Filing Summary

Medpace Holdings director Brian T. Carley exercised stock options to acquire 6,472 shares of common stock at $54.99 per share on 02/13/2026. Following this option exercise, he directly owned 32,753 shares of Medpace common stock. The exercised option had vested in full on May 14, 2020 and is now fully exhausted, with no derivative securities remaining from this grant.

Insider Trade Summary

6,472 shares exercised/converted

Mixed 2 txns

Insider Carley Brian T

Role Director

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	6,472	$0.00	--
Exercise	Common Stock	6,472	$54.99	$356K

Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct); Common Stock — 32,753 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carley Brian T

(Last) (First) (Middle)

C/O MEDPACE HOLDINGS, INC.

5375 MEDPACE WAY

(Street)

CINCINNATI OH 45227

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Medpace Holdings, Inc. [ MEDP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/13/2026		M		6,472	A	$54.99	32,753	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$54.99	02/13/2026		M			6,472	(1)	05/17/2026	Common Stock	6,472	$0	0	D

Explanation of Responses:

1. The option vested in full on May 14, 2020.

Remarks:

	/s/ Stephen P. Ewald, Attorney-in-Fact for Brian T. Carley	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Medpace Holdings (MEDP) report for Brian T. Carley?

Medpace director Brian T. Carley exercised stock options for 6,472 shares. On February 13, 2026, he converted an option grant into common stock, increasing his direct ownership while fully utilizing that particular option award.

At what price did Brian T. Carley exercise his Medpace (MEDP) stock options?

Brian T. Carley exercised his Medpace options at $54.99 per share. The Form 4 shows a transaction code M, indicating an option exercise that delivered 6,472 common shares at this exercise price.

How many Medpace (MEDP) shares does Brian T. Carley own after this Form 4 transaction?

After the transaction, Brian T. Carley directly owned 32,753 Medpace shares. The Form 4 lists this amount as his beneficially owned common stock following the reported option exercise on February 13, 2026.

What happened to the Medpace (MEDP) stock option that Brian T. Carley exercised?

The stock option was fully exercised and now has zero remaining derivative securities. It covered 6,472 shares, vested in full on May 14, 2020, and was completely converted into common stock in the February 13, 2026 transaction.

What does transaction code M mean in the Medpace (MEDP) Form 4 for Brian T. Carley?

Transaction code M indicates an exercise or conversion of a derivative security. In this case, Carley exercised a stock option, acquiring 6,472 shares of Medpace common stock rather than making an open-market purchase or sale.